Sapanisertib plus cabozantinib for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies a combination of two drugs for advanced liver cancer with a specific gene change. The goal is to see if adding sapanisertib to the usual cabozantinib treatment helps people live longer without their cancer growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer that is not curable with surgery or other local treatments.
- You have received at least one prior systemic treatment (for the phase 2 part).
- You have measurable disease as defined by imaging criteria.
- You have adequate organ function as shown by blood tests.
- You have a specific change (mutation) in the beta-catenin gene for the phase 2 part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether atezolizumab combined with a multi-targeted (“multi-kinase”) inhibitor can treat advanced liver cancer that cannot be cured with surgery or local procedures. It focuses on people whose cancer has already grown despite a first-line treatment using atezolizumab plus bevacizumab.
This trial studies a combination treatment for hepatocellular carcinoma (liver cancer) that cannot be removed with surgery or transplant. It adds cabozantinib and immunotherapy (ipilimumab plus nivolumab) to TACE, a procedure that delivers medicine directly to the liver tumor area.
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
This study tests the drug cabozantinib (a pill that stops cancer growth) for people whose liver cancer has progressed after standard first-line immunotherapy. The goal is to see if it can slow down or shrink the cancer.
This study tests a new drug, cabozantinib, for people with liver cancer that has grown despite previous treatment with atezolizumab and bevacizumab. The goal is to see if this drug can help control the cancer.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
Hear when a new Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.